Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT
NCT04067726Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2019
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab, sponsored by Washington University School of Medicine. Started Aug 2019; status: active, not recruiting.
02
Drugs
denosumab
Beyond the preview
Go deeper on NCT04067726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067726.